3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Classical hematology
1
Conditions
Leukemia, Myeloid, Acute
166
Leukemia
86
Precursor Cell Lymphoblastic Leukemia-Lymphoma
71
Lymphoma
51
Myelodysplastic Syndromes
38
Congenital Abnormalities
32
Burkitt Lymphoma
29
Lymphoma, Non-Hodgkin
27
Recurrence
26
Leukemia, Myelomonocytic, Acute
26
Leukemia, Monocytic, Acute
26
Lymphoma, Mantle-Cell
23
Leukemia, Erythroblastic, Acute
23
Leukemia, Megakaryoblastic, Acute
21
Hodgkin Disease
18
Lymphoma, Large B-Cell, Diffuse
17
Lymphoma, Follicular
13
Myeloproliferative Disorders
12
Leukemia, Myelomonocytic, Chronic
11
Leukemia, Biphenotypic, Acute
11
Leukemia, Eosinophilic, Acute
9
Blast Crisis
9
Lymphoma, B-Cell
8
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
8
Anemia, Refractory, with Excess of Blasts
8
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
7
Neoplasms
7
Multiple Myeloma
7
Leukemia, Basophilic, Acute
7
Leukemia, Lymphocytic, Chronic, B-Cell
6
Interventions
temsirolimus
1
sargramostim
1
ruxolitinib
1
rucaparib
1
pazopanib
1
olaparib
1
eltrombopag
1
cc-486
1
Surveys and Questionnaires
1
Nivolumab
1
Monatide (IMS 3015)
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Doxorubicin
1
Docetaxel
1
Diphenhydramine
1
Cytarabine
1
Cyclophosphamide
1
Azacitidine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Pathologic Complete Response
×
Cytarabine
×
Clear all
NCT01656252
2020-11-03
PrE0901
PrECOG, LLC.
Phase 1/2
Terminated
15 enrolled
5 charts